Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SAN DIEGO, Feb. 25, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, March 3, 2016 at 5:00 p.m. ET to report its fourth quarter and full year 2015 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-877-303-6235 (domestic) or 1-631-291-4837 (international) and refer to conference ID 58417776. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of immuno-oncology therapies, including off-the-shelf NK- and T-cell-based candidates derived from engineered induced pluripotent cells, and immuno-regulatory therapies, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 [email protected]
